Special Issue "Cancer Immunotherapy: Focus on Multidisciplinary Approaches and Predictive Biomarkers"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 15 November 2022 | Viewed by 501

Special Issue Editors

Prof. Dr. Nicola Silvestris
E-Mail Website
Guest Editor
Department of Human Pathology of the Adult and the Developmental Age "G. Barresi", University of Messina, Messina, Italy
Interests: gastrointestinal tumors; translational research; clinical trials
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Mariacarmela Santarpia
E-Mail Website
Guest Editor
Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Italy
Interests: thoracic tumors; melanoma; translational research
Dr. Tindara Franchina
E-Mail Website
Guest Editor
Medical Oncology Unit, Department of Human Pathology ‘G. Barresi’, University of Messina, Messina, Italy
Interests: thoracic oncology; cancer immunotherapy; precision oncology; translational research

Special Issue Information

Dear Colleagues,

A deeper understanding of the mechanisms involved in antitumor immunity has led to the development of a number of immunotherapies, including immune checkpoint inhibitors (ICIs), which have markedly changed the treatment scenario of hematological malignancies and solid tumors. Immune checkpoint inhibitors, including monoclonal antibodies directed against the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway or the cytotoxic T-lymphocyte antigen-4 (CTLA-4) pathway, currently represent the standard of care for the treatment of a large number of metastatic tumors and have also proven to be effective as part of multimodality therapeutic approaches to locally advanced and early-stage tumors. However, despite demonstration of significant clinical efficacy, initial objective responses to ICIs are still unsatisfactory, and almost all patients ultimately develop acquired resistance to treatment over time. Moreover, the development of immune-related adverse events can limit the use of these beneficial agents in the clinical setting. Hence, it is of crucial importance to identify predictive biomarkers to select those patients most likely benefiting from immunotherapy to improve patient outcomes while potentially avoiding toxicities with these drugs.

In this Special Issue, we will include research articles and reviews covering current knowledge and outlooks on predictive biomarkers in tissue and liquid biopsy and combinatorial therapeutic strategies integrating immunotherapy with radiotherapy, chemotherapy, and targeted agents, in different tumor types and settings of disease. Mechanisms and management of immune-related toxicities will also be discussed.

Prof. Dr. Nicola Silvestris
Prof. Dr. Mariacarmela Santarpia
Dr. Tindara Franchina
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • immune checkpoint inhibitors (ICIs)
  • predictive biomarkers
  • multidisciplinary treatments
  • immune-related toxicity

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients
Cancers 2022, 14(10), 2435; https://doi.org/10.3390/cancers14102435 - 14 May 2022
Viewed by 312
Abstract
Immune checkpoint inhibitors (ICIs) are largely used in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Novel biomarkers that provide biological information that could be useful for clinical management are needed. In this respect, extracellular vesicles (EV)-associated microRNAs (miRNAs) that are [...] Read more.
Immune checkpoint inhibitors (ICIs) are largely used in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). Novel biomarkers that provide biological information that could be useful for clinical management are needed. In this respect, extracellular vesicles (EV)-associated microRNAs (miRNAs) that are the principal vehicle of intercellular communication may be important sources of biomarkers. We analyzed the levels of 799 EV-miRNAs in the pretreatment plasma of 88 advanced NSCLC patients who received anti-PD-1 therapy as single agent. After data normalization, we used a two-step approach to identify candidate biomarkers associated to both objective response (OR) by RECIST and longer overall survival (OS). Univariate and multivariate analyses including known clinicopathologic variables and new findings were performed. In our cohort, 24/88 (27.3%) patients showed OR by RECIST. Median OS in the whole cohort was 11.5 months. In total, 196 EV-miRNAs out 799 were selected as expressed above background. After multiplicity adjustment, abundance of EV-miR-625-5p was found to be correlated with PD-L1 expression and significantly associated to OR by RECIST (p = 0.0366) and OS (p = 0.0031). In multivariate analysis, PD-L1 staining and EV-miR-625-5p levels were constantly associated to OR and OS. Finally, we showed that EV-miR-625-5p levels could discriminate patients with longer survival, in particular in the class expressing PD-L1 ≥50%. EV-miRNAs represent a source of relevant biomarkers. EV-miR-625-5p is an independent biomarker of response and survival in ICI-treated NSCLC patients, in particular in patients with PD-L1 expression ≥50%. Full article
Show Figures

Figure 1

Back to TopTop